This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.  Read our Cookies Policy.
Close
Eye News
  • Features
    • Close
    • Features
    • Allied Professions
    • Humanitarian
    • Interviews
    • AI & Oculomics
    • Ophthalmology
    • Optometry
    • Podcast videos
    • Supplements
  • Education
    • Close
    • Education
    • Learning Curve
    • Quiz
    • Top Tips
    • Trainees
    • Medico-Legal
    • The Truth Behind The Headlines
    • Case Reports
    • Pete's Bogus Journey
  • Reviews
    • Close
    • Reviews
    • Book Reviews
    • Journal Reviews
    • What's trending?
    • Tech Reviews
    • My Top Five
    • The Culture Section
  • Events
  • News
  • Product Guide
  • Industry News
  • Contact us
    • Close
    • Contact us
    • Write for Eye News
  • Home
  • Reviews
  • Journal Reviews
  • Intravitreal dexamethasone implant for diabetic macular oedema

Intravitreal dexamethasone implant for diabetic macular oedema
Reviewed by Brian Ang

1 February 2015 | Brian Ang | EYE - Paediatrics, EYE - Strabismus

The authors report on the three-year outcomes of the Ozurdex Dexamethasone (DEX) intravitreal implant multi-centre trial for the treatment of diabetic macular oedema (DME). Patients with DME (best-corrected vision of 20/50 to 20/200 and central retinal thickness of ≥300µm) were randomised in a 1:1:1 ratio to DEX implant 0.7mg, DEX implant 0.35mg or sham. Exclusion criteria included uncontrolled diabetes, concurrent use of systemic steroid, glaucoma, active neovascularisation, history of intraocular laser or surgery within 90 days, intravitreal anti-VEGF injection within 90 days, and intravitreal triamcinolone injection within 180 days. There were 1048 patients enrolled, but only 607 (57.9%) completed the three year study duration. The average number of treatments was 5.0 in the DEX implant 0.7mg group, 5.2 in the DEX implant 0.35mg group, and 5.1 in the sham group. In terms of visual acuity improvement of >15 letters, this was achieved in 22.2% of the DEX implant 0.7mg group, in 18.4% of the DEX implant 0.35 group, and in 12.0% of the sham group. The average reduction in central retinal thickness was 111.6µm in the DEX 0.7mg group, 107.9µm in the DEX 0.35mg group, and 41.9µm in the sham group. The commonest complications were elevated intraocular pressure (IOP) and cataract. IOP elevation requiring topical medication occurred in 41.5% in the DEX 0.7mg group, 37.6% in the DEX 0.35mg group, and 9.1% in the sham group. Cataract surgery was required in 59.2% of phakic eyes. In comparison to sham, the Ozurdex intravitreal implant show significant visual improvement and reduction in central retinal thickness. The side-effect profile was less in comparison to those previously reported for intravitreal fluocinolone and triamcinolone, but still significant nonetheless. A trial comparing Ozurdex to intravitreal anti-VEGF injections for DME will help to establish whether the benefit of reduced numbers of injections is outweighed by the significant side-effect profile.

Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular oedema.
Boyer DS, Yoon YH, Belfort Jr B, et al.
OPHTHALMOLOGY
2014;121:1904-14.
Share This
CONTRIBUTOR
Brian Ang

Royal Victorian Eye and Ear Hospital, Melbourne, Australia

View Full Profile
Specialty
  • EYE - Cataract
  • EYE - Cornea
  • EYE - General
  • EYE - Glaucoma
  • EYE - Neuro-ophthalmology
  • EYE - Oculoplastic
  • EYE - Oncology
  • EYE - Orbit
  • EYE - Paediatrics
  • EYE - Pathology
  • EYE - Refractive
  • EYE - Strabismus
  • EYE - Vitreo-Retinal
Archive
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013

Top Of Page

9 Gayfield Square, 
Edinburgh EH1 3NT, UK.

Call: +44 (0)131 557 4184
www.pinpoint-scotland.com

WEBSITE DETAILS
  • Cookie Policy
  • Data Protection Notice
  • Privacy Policy
  • Terms and Conditions
ABOUT US
  • Who we are
  • Register
  • Contact us
  • Contributors
  • Company Awards
DIGITAL ISSUES/GUIDELINES
  • Digital issues - Library
  • Supplements - Library
  • Guidelines
Accreditations
IPSO_FLAG_TEAL 2025.png cpdcertified.png

Pinpoint Scotland Ltd (Registered in Scotland No. SC068684) | © 2025 - Website by Gecko Agency